Skip to content
Product Line: Pharmaceutical Chemicals

Upadacitinib

CAS 1310726-60-3

Molecular structure of Upadacitinib

CAS · 1310726-60-3

01

Product Overview

Upadacitinib is a high-purity a-api supplied for industrial and specialty chemical applications. Contact our team for specifications, packaging options and lead times.

02

Product Specifications

Appearance White, off-white to yellow to brown solid
Identification by NMR The test sample is consistent with the nuclear magnetic resonance (NMR) of the test sample
Related Substances by HPLC Purity 99.0% min
Any Single Impurity 0.5% max
Assay on Dried Basis (w/w) 98.0% min
Water Content by KF 3.0% max
Residue on Ignition 0.20% max
Heavy Metals 10 ppm max
03

Applications

1. Therapeutic Use

a. Rheumatoid Arthritis (RA)

● Approved as a monotherapy or in combination with methotrexate for adults with moderate to severe RA who have had an inadequate response to TNF blockers or other DMARDs.

b. Psoriatic Arthritis (PsA)

● Treats active PsA in patients unresponsive to conventional therapies or biologics.

c. Atopic Dermatitis

● Approved for moderate to severe atopic dermatitis, particularly in adults and adolescents (12 years and older) who are not adequately controlled with topical medications.

d. Ulcerative Colitis (UC)

● Used for moderate to severe UC as an oral alternative to corticosteroids and biologics.

e. Ankylosing Spondylitis & Axial Spondyloarthritis

● Indicated for adults with active ankylosing spondylitis or non-radiographic axial spondyloarthritis.

04

Benefits

1. Targeted Immunomodulation

● Offers precise control of immune signaling pathways, reducing inflammation while preserving broader immune function.

2. Oral Administration

● Taken once daily as an oral tablet, providing a convenient alternative to injectable biologics like TNF inhibitors.

3. Rapid Onset of Action

● Clinical studies show symptom relief within weeks, making it suitable for patients requiring quick therapeutic impact.

4. Wide Indication Spectrum

● Approved across multiple chronic autoimmune diseases, reducing the need for multiple medications in comorbid conditions.

05

Conclusion

A concise summary and suitability assessment for this product is available on request. Contact our team to discuss whether it fits your process and quality requirements.